Inozyme Pharma, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas A. Treco
- Full Time Employees
- 67
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 321 Summer Street Boston MA United States of America 02210
- IPO Date
- Jul 24, 2020
- CIK
- 0001693011
- Website
- inozyme.com
- Similar Companies
- Business
- Inozyme Pharma, Inc. (INZY) develops enzyme replacement therapies targeting disruptions in the PPi-Adenosine Pathway to treat rare genetic diseases characterized by pathologic mineralization and intimal proliferation, including ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis; its lead product candidate, INZ-701, an ENPP1 Fc fusion protein, advances in late-stage pivotal clinical trials for pediatric and adult ENPP1 Deficiency, with Phase III studies planned for pediatric ABCC6 Deficiency and ongoing evaluations in infants and for calciphylaxis; the company additionally pursues next-generation enzyme replacement therapy for ossification of the posterior longitudinal ligament and preclinical gene therapy programs for related disorders. Founded in 2015 and headquartered in Boston, Massachusetts, Inozyme operates as a clinical-stage biopharmaceutical company focused on patients with severe metabolic dysregulation affecting bone, vasculature, soft tissue, and skeleton, primarily in the United States and globally through clinical development. In July 2025, BioMarin Pharmaceutical Inc. completed its acquisition of Inozyme for approximately $270 million in an all-cash transaction at $4.00 per share, integrating INZ-701 into BioMarin's enzyme therapy portfolio and delisting INZY from Nasdaq, following a definitive agreement announced in May 2025.
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401
BioMarin Announces Completion of Acquisition of Inozyme
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHTR and INZY on Behalf of Shareholders
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
BioMarin Strengthens Enzyme Therapy Business with Acquisition of Inozyme Pharma
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701